Ocular Therapeutix, Inc.

NasdaqGM:OCUL Stock Report

Market Cap: US$1.8b

Ocular Therapeutix Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:OCUL Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Jun 26SellUS$122,628Nadia WaheedIndividual14,828US$8.27
26 May 26SellUS$24,748Jeffrey HeierIndividual3,018US$8.20
26 May 26SellUS$24,329Peter KaiserIndividual2,967US$8.20
26 May 26SellUS$173,479Pravin DugelIndividual21,156US$8.20
26 May 26SellUS$15,236Sanjay NayakIndividual1,858US$8.20
23 Feb 26SellUS$25,312Jeffrey HeierIndividual3,057US$8.28
23 Feb 26SellUS$14,565Sanjay NayakIndividual1,759US$8.28
23 Feb 26SellUS$23,267Peter KaiserIndividual2,810US$8.28
23 Feb 26SellUS$166,064Pravin DugelIndividual20,056US$8.28
20 Feb 26BuyUS$461,354Richard LindstromIndividual60,229US$7.66
20 Feb 26SellUS$27,167Nadia WaheedIndividual3,510US$7.74
12 Feb 26SellUS$71,082Nadia WaheedIndividual7,863US$9.04
12 Feb 26SellUS$1,128,933Pravin DugelIndividual124,882US$9.04
12 Feb 26SellUS$93,546Sanjay NayakIndividual10,348US$9.04
12 Feb 26SellUS$103,472Donald NotmanIndividual11,446US$9.04
04 Feb 26SellUS$101,398Donald NotmanIndividual11,490US$9.14
24 Nov 25SellUS$41,767Jeffrey HeierIndividual3,469US$12.04
24 Nov 25SellUS$36,144Peter KaiserIndividual3,007US$12.02
24 Nov 25SellUS$235,141Pravin DugelIndividual19,530US$12.04
24 Nov 25SellUS$22,611Sanjay NayakIndividual1,878US$12.04
05 Nov 25SellUS$277,790Namrata SarojIndividual25,865US$10.74
08 Oct 25SellUS$137,369Todd AndermanIndividual11,132US$12.34
02 Oct 25SellUS$115,942Jeffrey HeierIndividual10,502US$11.04
02 Oct 25SellUS$106,473Peter KaiserIndividual9,653US$11.03
02 Sep 25SellUS$13,250Donald NotmanIndividual1,066US$12.43
25 Aug 25SellUS$258,788Pravin DugelIndividual21,494US$12.04
25 Aug 25SellUS$36,879Jeffrey HeierIndividual3,063US$12.04
25 Aug 25SellUS$22,695Sanjay NayakIndividual1,885US$12.04
25 Aug 25SellUS$36,252Peter KaiserIndividual3,011US$12.04

Insider Trading Volume

Insider Buying: OCUL insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of OCUL?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,559,3771.17%
General Public9,248,5894.22%
Hedge Funds12,315,0005.62%
VC/PE Firms19,686,2828.99%
Institutions175,151,11080%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 37.5%.

Top Shareholders

Top 25 shareholders own 74.99% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.9%
FMR LLC
32,653,341US$266.5m2.73%0.01%
8.99%
Deep Track Capital, LP
19,686,282US$160.6m144%2.98%
7.37%
BlackRock, Inc.
16,132,931US$131.6m3.4%no data
5.62%
Avoro Capital Advisors LLC
12,315,000US$100.5m14.3%1.2%
5.43%
Summer Road LLC
11,879,825US$96.9m6.94%69.9%
4.73%
VR Management, LLC
10,346,926US$84.4m50.8%2.8%
3.98%
Vanguard Capital Management, LLC
8,719,039US$71.1m0%no data
2.69%
T. Rowe Price Group, Inc.
5,897,149US$48.1m3,340%no data
2.53%
Point72 Asset Management, L.P.
5,534,985US$45.2m445%0.07%
2.15%
State Street Global Advisors, Inc.
4,708,419US$38.4m12.2%no data
2.07%
Geode Capital Management, LLC
4,529,185US$37.0m3.96%no data
1.89%
AllianceBernstein L.P.
4,129,687US$33.7m-4.89%0.01%
1.76%
Logos Global Management, L.P.
3,850,000US$31.4m10%1.76%
1.45%
Octagon Capital Advisors LP
3,166,600US$25.8m20.7%2.88%
1.23%
Balyasny Asset Management L.P.
2,692,622US$22.0m253%0.04%
1.18%
Commodore Capital LP
2,575,000US$21.0m0%1.16%
1.07%
Deltec Asset Management LLC
2,340,620US$19.1m-5.92%3.18%
0.84%
Two Sigma Investments, LP
1,830,159US$14.9m381%0.01%
0.84%
UBS Asset Management AG
1,829,537US$14.9m17.8%no data
0.76%
Woodline Partners LP
1,667,609US$13.6m0.09%0.05%
0.75%
TCG Crossover Management, LLC
1,647,752US$13.4m-71.3%0.39%
0.73%
Vanguard Portfolio Management, LLC
1,594,666US$13.0m0%no data
0.7%
Northern Trust Global Investments
1,525,626US$12.4m4.32%no data
0.68%
Defilade Capital Management, L.P.
1,487,645US$12.1m118%1.73%
0.67%
Charles Schwab Investment Management, Inc.
1,461,177US$11.9m0.05%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 19:10
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ocular Therapeutix, Inc. is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Anita DushyanthBerenberg
Tazeen AhmadBofA Global Research